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Background
Rift Valley fever is a mosquito-borne viral zoonotic disease 
that affects sheep, goats, cattle and camels causing devastating 
losses, especially among pastoral communities that rely on 
livestock for their livelihoods. The disease occurs in explosive 
outbreaks following periods of above-normal and persistent 
rainfall. 
People can become infected with Rift Valley fever after being 
bitten by an infected mosquito or through close contact with 
acutely infected animals or their tissues. In people, the disease 
manifests itself as a mild influenza-like syndrome in over 
80% of cases or a severe disease with haemorrhagic fever, 
encephalitis or retinitis in a few cases.
Because of its episodic occurrence and predilection for 
remote pastoral areas, the impact of the disease is often 
exacerbated by delays in the deployment of prevention and 
control measures, frequently due to a lack of pre-allocated 
funds for financing emergency measures.
Livestock vaccination is regarded as the most reliable 
method for controlling the disease. However, an assessment 
of emergency vaccination programs implemented after the 
2007–08 Rift Valley fever outbreak in eastern Africa and during 
the 2015 scare showed that vaccination levels achieved were 
too low to make a difference.
Current vaccination approaches have been proven to be 
ineffective, partly because the risk of Rift Valley fever in eastern 
Africa evolves rapidly and usually there is not enough time to 
plan and execute interventions. In addition, areas where the 
disease is endemic are usually inaccessible during the high-
risk periods due to excessive rainfall and flooding preceding 
outbreaks.
Objectives
This project, therefore, aims to develop optimal Rift Valley 
fever vaccination strategies that combine periodic preventive 
vaccination and reactive vaccination in the high-risk 
periods to replace the current practice where only reactive 
vaccination is implemented after warnings of heightened 
disease risk have been issued. Scientists will seek to use 
the findings generated from the project to develop Rift 
Valley fever vaccination strategies which could be used by 
policymakers throughout the eastern Africa region.
Project activities
• Development of best-bet Rift Valley fever 
vaccination strategies. Desk research—including 
mathematical modelling—will be undertaken and 
stakeholder workshops organized to develop optimal 
Rift Valley fever vaccination strategies. The model will be 
used to evaluate the impact of alternative vaccination 
strategies under varied Rift Valley fever virus transmission 
patterns. It will also be formulated to account for key 
processes that influence herd immunity dynamics, such as 
livestock turn-over rates and decay rates of neutralizing 
antibodies. Policymakers and other relevant stakeholders 
will be involved in the evaluation of vaccination options 
identifying strategies that enhance opportunities for the 
participation and engagement of women.
• Refining of the Rift Valley fever decision support 
framework. The lessons learned from the activities 
outlined above will be used to refine the existing decision 
support framework and contingency plans. It is anticipated, 
for instance, that the development of new vaccination 
strategies will be described in these policy documents.
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identified through modelling, and those found to be 
sustainable will be developed further for use.
• Undertaking of field- and laboratory-based 
vaccination response studies. It is often assumed 
that vaccination confers life-long protection to hosts, 
but little research has been undertaken to verify this 
assumption. Even if protective antibodies were to persist 
for a lifetime in a vaccinated host, the high turn-over rates 
of livestock—particularly in Rift Valley fever-endemic 
areas—would have a substantial impact on herd immunity. 
Longitudinal studies involving vaccinated cattle, sheep and 
goats will be implemented in Rift Valley fever-endemic 
sites to determine changes in protective antibody titres 
over time and rates of replacement of vaccinated animals 
in a herd. Virus neutralization assays will also be used to 
determine whether the potency of antibodies generated 
from vaccination can be maintained over a period of 
one year. Some of the data generated from this trial will 
be used to validate the transmission model used under 
activity one above to develop vaccination strategies.
• Identification of factors influencing the uptake 
of Rift Valley fever vaccines. Previous surveys have 
shown that Rift Valley fever vaccination campaigns in 
many areas in East Africa often attain very low levels 
of coverage which may not be enough to prevent an 
outbreak. This could be attributed to a range of factors, 
including institutional challenges that limit vaccine 
delivery and socio-cultural issues that limit uptake at 
community level. Extensive socio-economic studies 
will be conducted to identify these factors and ways 
of addressing them. Special attention will be paid to 
understanding gender roles in disease management and 
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